melanotan 2 dosage tanning: Frequently asked questions

Maintain dosing at 0.25–0.5mg twice weekly indefinitely once target pigmentation is achieved. MT-2-induced melanin is stable in the epidermis for approximately 28 days (the natural keratinocyte turnover cycle), so twice-weekly dosing compensates for ongoing pigment degradation. Without UV exposure, your tan will be 1–2 shades lighter than the maximum achievable with combined MT-2 and UV protocols. UV synergizes with melanocortin signaling to upregulate additional melanogenic pathways that MT-2 alone does not activate. Reduce dose frequency if you notice further darkening over time, indicating receptor sensitivity is increasing with chronic exposure.

Increase your dose to 0.75mg daily and add controlled UV exposure (10–15 minutes per session, 2–3 times weekly). Some individuals with low baseline MC1R expression require higher receptor occupancy to initiate melanogenesis. The absence of pigment change at 0.5mg suggests you're below your personal saturation threshold. Monitor for mole darkening as an early indicator of melanocyte activation even before visible skin pigmentation appears. If no change occurs after an additional 10 days at 0.75mg with UV exposure, you may have a genetic MC1R polymorphism (common in red-haired individuals) that reduces receptor responsiveness to synthetic agonists. MT-2 is unlikely to produce meaningful tanning in this population.

Reduce your dose by 50% (from 0.5mg to 0.25mg, or from 0.25mg to 0.125mg) and hold at that level for 7 days before attempting further titration. Nausea peaking within 2–4 hours post-injection indicates MC4R overstimulation. Your baseline receptor sensitivity is higher than average, and the standard starting dose exceeds your saturation threshold. Inject in the evening on an empty stomach and consider taking 1g ginger root extract 30 minutes before dosing. If nausea persists beyond 6 hours or prevents eating, discontinue MT-2 and consult a healthcare provider. Persistent symptoms may indicate an idiosyncratic reaction rather than dose-dependent MC4R activation.

Reduce to 0.25mg daily and extend the loading phase to 14–21 days. Nausea severity correlates with dose escalation speed. Slower titration allows MC4R desensitization, reducing gastrointestinal distress. Take the injection with food and avoid dosing within three hours of vigorous physical activity, which amplifies nausea through increased gut motility. If nausea persists beyond one week at 0.25mg, Melanotan-2 may not be tolerable at any therapeutic dose.

Discard it immediately. Cloudiness indicates bacterial contamination or peptide aggregation, both of which render the solution unsafe and ineffective. Melanotan-2 in bacteriostatic water should remain clear and colorless. Yellow, brown, or opaque solutions signal protein denaturation or microbial growth. Never inject cloudy peptides under any circumstance. The risk of infection outweighs any potential tanning benefit.

Resume at the last tolerated dose rather than restarting at 0.25mg. Missing doses during loading delays visible pigmentation by 5–7 days but does not reset receptor upregulation entirely. MC1R density remains elevated for 48–72 hours post-injection, so a three-day gap reduces cumulative activation without erasing progress. Continue the loading phase for an additional 3–5 days to compensate for missed exposures.